Holen Sie sich die Stockscreener-App
1.24
3.31%
0.03
Schlusskurs vom Vortag:
$1.21
Offen:
$1.21
24-Stunden-Volumen:
266.92K
Relative Volume:
0.24
Marktkapitalisierung:
$76.81M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.4013
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+2.46%
1M Leistung:
-20.38%
6M Leistung:
-3.85%
1J Leistung:
-90.73%
1-Tages-Spanne:
$1.19
$1.25
1-Wochen-Bereich:
$1.19
$1.27
52-Wochen-Spanne:
$1.1001
$14.26
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.25 | 74.35M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.50 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.41 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Can Pliant Therapeutics Inc. stock double in next 5 yearsTrade Volume Summary & Long-Term Safe Investment Ideas - DonanımHaber
Pliant Therapeutics appoints Minnie Kuo as COO - MSN
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transition2025 Buyback Activity & Verified Chart Pattern Signals - Улправда
Is Pliant Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Free Professional Investment Consultations - earlytimes.in
What analysts say about Pliant Therapeutics Inc stockStock Screening Results & Free Explosive Wealth Accumulation - earlytimes.in
Pliant Therapeutics appoints Minnie Kuo as chief operating officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics appoints Minnie Kuo as chief operating officer - Investing.com
Pliant Therapeutics Appoints Minnie Kuo as COO - TipRanks
Pliant Therapeutics Appoints New Chief Operating Officer - TradingView — Track All Markets
Pliant Therapeutics (NASDAQ: PLRX) names Minnie Kuo Chief Operating Officer - Stock Titan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics, Inc. (PLRX) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre - Investing.com Nigeria
Pliant Therapeutics Announces Departure of Chief Medical Officer - TradingView
Pliant Therapeutics Inc (PLRX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre By Investing.com - Investing.com South Africa
Pliant Therapeutics shares rise after early cancer drug data impresses - MSN
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga
Pliant Therapeutics reports interim PLN-101095 Phase I trial data - Yahoo
Pliant’s PLN-101095 shows promising results in cancer trial By Investing.com - Investing.com Nigeria
Can Pliant Therapeutics Inc. stock sustain revenue growthJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - Newser
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), uniQure (QURE) and Medtronic (MDT) - The Globe and Mail
What hedge fund moves indicate for Pliant Therapeutics Inc. (9PT) stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - Newser
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerBear Alert & Risk Controlled Daily Plans - Newser
Why Is Pliant Therapeutics Stock Trading Lower TodayPliant Therapeutics (NASDAQ:PLRX) - Benzinga
Pliant Therapeutics, Inc. (PLRX) -15.3% in Intraday Trading: Interim Data Announcement Fails to Support Price - Stocks Telegraph
Pliant Therapeutics stock jumps on promising cancer drug trial results By Investing.com - Investing.com South Africa
Pliant Therapeutics stock jumps on promising cancer drug trial results - Investing.com
Pliant Therapeutics, Inc. Announces Interim Data from Pln-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - marketscreener.com
Pliant’s PLN-101095 shows promising results in cancer trial - Investing.com India
Pliant Therapeutics reveals promising early results for PLN-101095 - Traders Union
Pliant Therapeutics announces interim data from PLN-101095 - marketscreener.com
Pliant Therapeutics (Nasdaq: PLRX) reports interim PLN-101095 data with 1 CR, 3 PRs - Stock Titan
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Sahm
Is Pliant Therapeutics Inc. (9PT) stock considered safe havenTrade Volume Report & Community Consensus Stock Picks - Newser
Are Smart Investors Making the Right Decision? Pliant Therapeutics Inc (PLRX) - setenews.com
Will Pliant Therapeutics Inc. (9PT) stock profit from fiscal stimulusMarket Risk Summary & Verified Swing Trading Watchlist - Newser
Will Pliant Therapeutics Inc. stock attract more institutional investors - Newser
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - Investing News Network
Pliant Therapeutics Inc Stock Analysis and ForecastRSI Overbought/Oversold & Insights From Wall Street Professionals - earlytimes.in
What drives Pliant Therapeutics Inc stock priceCapital Gains Strategies & Access Advanced Stock Screening Tools - earlytimes.in
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pliant Therapeutics Inc-Aktie (PLRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.63%
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):